Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
More News related to CYPB
- Trading Outlook for Hard To Treat Diseases Inc. Issued by InvestorSoup.com
- Cypress Bioscience Announces Third Quarter 2009 Financial Results
- Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
- Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference
- Forest Lab (FRX) and Cypress Bio (CYPB) Announce Savella Phase III Results
More News related to Upgrades
- Wunderlich Securities Downgrades Gran Tierra Energy (GTE) to Hold
- Stephens Downgrades Benihana (BNHN) to Equalweight
- UBS Downgrades NRG Energy (NRG) to Neutral; Cuts Target to $26
- Citi Cuts Lukoil (LUKOY) to Hold
- RBC Upgrades Diamond Rock (DRH) to Outperform, Downgrades Hospitality Properties (HPT) to Sector Perform
Oppenheimer upgrades Cypress Bioscience (Nasdaq: CYPB) from Perform to Outperform. Price target $9.
To see more analyst ratings on CYPB Click Here.
Cypress Bioscience, Inc. provides therapeutics and personalized medicine services.
Related Categories
UpgradesStocks Mentioned
+0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
